CompletedNot Applicable

Randomized Trial of HIFU vs. Cryo for Prostate Cancer

United States50 participantsStarted 2023-04-01

Plain-language summary

HIFU has been FDA approved and is widely utilized across the United States and Europe for the treatment of prostate cancer. Despite this, HIFU has not been offered within SCPMG until now due to growing patient demand. We have offered cryoablation. This pilot study will determine the efficacy of HIFU vs. cryoablation focal therapy for early stage prostate cancer within SCPMG. We hope to elucidate whether outcomes are similar between the two modalities.

Who can participate

Age range40 Years – 80 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All men age 40 or older with Gleason group 1 or 2 prostate cancer involving a single or adjacent sextants
✓. PSA \< 10
✓. mpMRI without extracapsular extension or seminal vesicle invasion (non-focal MRI or organ confined)
✓. mpMRI which is either nonfocal or concordant with biopsy.

Exclusion criteria

✕. Gleason group 3 or higher
✕. Multifocal disease
✕. mpMRI with ECE or SVI
✕. PSA \> 10
✕. Active anorectal disease
✕. Age \> 80

What they're measuring

In-field cancer persistence

Timeframe: 3 months

Trial details

NCT IDNCT06929065

SponsorKaiser Permanente

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-01

View on ClinicalTrials.gov More Prostate Cancer trials